Mast Therapeutics, Inc. (MSTX)

[BooDog]

Mast To Present New Data Supporting Vepoloxamer (MST-188) In Sickle Cell Disease At 9th Annual Sickle Cell Disease Research And Education Symposium And 38th National Sickle Cell Disease Scientific Meeting

By PR Newswire, April 09, 2015, 08:00:00 AM EDT


Vote up

loading
A A A





- Vepoloxamer shown to improve properties of sickle red blood cells

- Reduced fragility / hemolysis

- Reduced adhesiveness

- Company also presenting at Investigational Drug Symposium and at the Technology Session with an overview of its mobile app for the sickle cell community, VOICE Crisis Alert™


Read more: http://www.nasdaq.com/press-release/mast-to-present-new-data-supporting-vepoloxamer-mst188-in-sickle-cell-disease-at-9th-annual-sickle-20150409-00291#ixzz3Wog4dsNh



Additionally, the Company's CEO, Brian M. Culley, will participate with a presentation entitled, "Epic Considerations for the EPIC Clinical Trial," in the Investigational Drug Symposium, taking place on Sunday, April 12, 2015, chaired by Susan Perrine, M.D., Professor of Medicine, Pediatrics and Pharmacology and Experimental Therapeutics at Boston University School of Medicine.

The Company also will participate in the Symposium's Technology Session entitled, "Striving for a Unified mHealth Strategy for Research and Clinical Care in Sickle Cell Disease," with a presentation by Gregory D. Gorgas, Senior Vice President, Commercialization, that will feature the free mobile app VOICE Crisis Alert™, which was developed by the Company for individuals with sickle cell disease to track and communicate their crises with their healthcare providers and caregivers.

Abstract Information:

•An abstract entitled, "Evaluation of purified poloxamer-188 (vepoloxamer) on sickle red blood cell (RBC) adhesion and membrane fragility utilizing microfluidic-based flow adhesion bioassays," by Patrick C. Hines M.D., Ph.D., Jennell White, Ph.D., Xiufeng Gao, M.D., and Ke Liu, Ph.D. of Functional Fluidics and R. Martin Emanuele, Ph.D. of Mast Therapeutics, Inc. summarizes the study data to be presented.


•The abstract is available on the Company's website at www.masttherapeutics.com/technology/publications/.

http://www.masttherapeutics.com/wp-content/uploads/2015/02/JSCDH-S-15-00089.pdf



EXCELLENT